Premium
Superparamagnetic iron oxide nanoparticles change endothelial cell morphology and mechanics via reactive oxygen species formation
Author(s) -
Buyukhatipoglu Kivilcim,
Clyne Alisa Morss
Publication year - 2011
Publication title -
journal of biomedical materials research part a
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.849
H-Index - 150
eISSN - 1552-4965
pISSN - 1549-3296
DOI - 10.1002/jbm.a.32972
Subject(s) - biophysics , reactive oxygen species , actin cytoskeleton , cytoskeleton , materials science , viability assay , endothelial stem cell , iron oxide nanoparticles , nanoparticle , actin , oxidative stress , cell , microbiology and biotechnology , nanotechnology , in vitro , chemistry , biology , biochemistry
Superparamagnetic iron oxide nanoparticles are used in various medical applications including magnetic resonance imaging, magnetic hyperthermia, and targeted drug and gene delivery. When used in vivo, these nanoparticles interact with endothelial cells lining all blood vessels, therefore it is crucial to understand endothelial cell functional changes and toxicity upon nanoparticle exposure. We incubated porcine aortic endothelial cells with varying concentrations of bare iron oxide nanoparticles (20–40 nm), and measured cellular reactive oxygen species (ROS) formation, morphology and cytoskeletal organization, death, and elastic modulus. Intracellular ROS increased more than 800% after 3 h of nanoparticle exposure (0.5 mg mL −1 ). Endothelial cells elongated to more than twice their initial length by 12 h, and actin stress fibers formed within the cells. This change in the actin cytoskeleton increased cell elastic modulus by 50%. When ROS formation was blocked using scavengers, initial cell morphology and the actin cytoskeleton remained intact, and cell viability increased. These studies suggest that iron oxide nanoparticles induce ROS formation, which disrupts the actin cytoskeleton and alters endothelial cell morphology and mechanics. If ROS formation is decreased using ROS inhibitors, either as a component of the nanoparticle coating or by systemic administration, higher nanoparticle concentrations might be used with greater efficacy and diminished side effects. © 2010 Wiley Periodicals, Inc. J Biomed Mater Res Part A, 2010.